NYSEARCA:XPH SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News $40.86 -0.17 (-0.42%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsBuy This Stock About SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XPH alerts:Sign Up Key Stats Today's Range$40.54▼$40.8850-Day Range$36.65▼$44.5652-Week Range$35.22▼$48.76Volume3,254 shsAverage Volume47,568 shsMarket Capitalization$147.09 millionAssets Under Management$141.67 millionDividend Yield1.62%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF OverviewSPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More… SPDR S&P Pharmaceuticals ETF ExpensesTypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.57%0.57%0.52%0.53%Other Expenses0.00%0.30%0.49%0.56%0.52%Total Expense0.35%0.70%0.72%0.73%0.71%Fee Waiver0.00%-0.45%-0.49%-0.65%-0.54%Net Expense0.35%0.61%0.63%0.58%0.60% Receive XPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XPH ETF News HeadlinesCapture European Growth with This Banking-Focused ETFApril 22, 2025 | theglobeandmail.comSPDR S&P Biotech ETF declares quarterly distribution of $0.0053March 24, 2025 | msn.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 5, 2025 | Brownstone Research (Ad)SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1548December 23, 2024 | msn.comSPDR® S&P Regional Banking ETFDecember 20, 2024 | morningstar.com1 No-Brainer Small-Cap S&P Index Fund to Buy Right Now for Less Than $200November 21, 2024 | msn.comSee More Headlines XPH ETF - Frequently Asked Questions How have XPH shares performed this year? SPDR S&P Pharmaceuticals ETF's stock was trading at $42.99 on January 1st, 2025. Since then, XPH shares have decreased by 5.0% and is now trading at $40.8590. View the best growth stocks for 2025 here. Who are SPDR S&P Pharmaceuticals ETF's major shareholders? SPDR S&P Pharmaceuticals ETF's top institutional investors include Kingsview Wealth Management LLC (7.24%), First Citizens Bank & Trust Co. (3.30%), Envestnet Portfolio Solutions Inc. (3.15%) and U.S. Capital Wealth Advisors LLC (0.41%). How do I buy shares of SPDR S&P Pharmaceuticals ETF? Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Pharmaceuticals ETF investors own include NVIDIA (NVDA), Pfizer (PFE), Adobe (ADBE), Applied Materials (AMAT), Chevron (CVX), JPMorgan Chase & Co. (JPM) and Meta Platforms (META). Fund Details IssuerSSgA Fund NameSPDR S&P Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XPH Inception Date6/19/2006 Fund ManagerMichael Feehily, Karl Schneider, Keith Richardson Webwww.spdrs.com Phone+1-617-6644738Fund Focus Asset ClassEquity BenchmarkS&P Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings51 Fund Statistics Assets Under Management$141.67 million Average Daily Volume$62,460.30 Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume20 Put Options20 Call Options7 Short Interest1,690,000 shs Miscellaneous Outstanding Shares3,600,000Beta0.67 Creation Unit50,000 Creation Fee$250.00 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report Top 10 XPH HoldingsCorcept Therapeutics (NASDAQ:CORT)Holding Weight: 5.09%Tarsus Pharmaceuticals (NASDAQ:TARS)Holding Weight: 4.32%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.25%Johnson & Johnson (NYSE:JNJ)Holding Weight: 4.10%Perrigo (NYSE:PRGO)Holding Weight: 3.97%Prestige Consumer Healthcare (NYSE:PBH)Holding Weight: 3.94%Zoetis (NYSE:ZTS)Holding Weight: 3.94%Eli Lilly and Company (NYSE:LLY)Holding Weight: 3.88%Axsome Therapeutics (NASDAQ:AXSM)Holding Weight: 3.79%Pfizer (NYSE:PFE)Holding Weight: 3.72%Full Holdings DetailsXPH Sector ExposureXPH Industry Exposure This page (NYSEARCA:XPH) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.